Business Context and Reporting Period
Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: MannKind is a biopharmaceutical company in the development stage, focused on therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA (an ultra rapid-acting inhaled insulin), is awaiting FDA approval. The company has incurred cumulative net losses of approximately $1.7 billion since inception and has no commercial products currently generating significant revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $93 | $0 |
| Net Loss | $(86,951) | $(115,016) |
| Net Loss Per Share (Basic & Diluted) | $(0.77) | $(1.13) |
| Operating Expenses | $77,957 | $111,192 |
| Research & Development (R&D) | $56,651 | $82,738 |
| General & Administrative (G&A) | $21,306 | $28,454 |
| Cash Used in Operating Activities | $(74,834) | $(105,022) |
| Cash and Cash Equivalents (End of Period) | $28,358 | $31,328 |
| Total Debt (Notes Payable & Convertible Notes) | $355,030 | $277,765 |
| Stockholders' Deficit | $(137,662) | $(59,221) |
Material Changes vs. Prior Period
- Revenue: Recognized $93,000 in revenue during the six months ended June 30, 2010, compared to zero in the prior year period, derived from a license agreement.
- Net Loss Reduction: Net loss decreased by approximately $28 million (24%) compared to the same period in 2009, driven primarily by reduced operating expenses.
- Expense Reductions:
- R&D Expenses: Decreased by $26.1 million (32%) due to lower clinical development costs for AFREZZA, reduced manufacturing costs, and a reduction in force implemented in April 2009.
- G&A Expenses: Decreased by $7.1 million (25%) due to lower salary-related costs and the non-recurrence of costs related to a prior Pfizer transaction.
- Debt Increase: Borrowings under the related-party loan arrangement increased by $77 million, raising the outstanding principal to $242 million. This increased interest expense by approximately $2.8 million compared to the prior year.
- Liquidity: Cash and cash equivalents decreased by $1.7 million during the period, though the company maintains $108 million in available borrowings under its related-party credit facility.
Outlook, Risks, and Management Commentary
- Regulatory Status: In March 2010, the FDA issued a Complete Response letter regarding the AFREZZA New Drug Application (NDA). In July 2010, the FDA accepted the company's reply and set a target action date of December 29, 2010. Approval is not guaranteed.
- Liquidity and Going Concern: Management believes existing capital resources (cash and available borrowings) will fund operations through the first quarter of 2011. However, the company explicitly states there is "substantial doubt" about its ability to continue as a going concern if it cannot raise additional capital or secure a strategic collaboration.
- Financing Plans: The company filed a shelf registration statement in April 2010 to sell up to $200 million of equity and debt securities. It is actively seeking strategic business collaborations for AFREZZA and its cancer programs.
- Key Risks:
- Failure to obtain FDA approval for AFREZZA.
- Inability to raise additional capital on favorable terms.
- Dependence on a single product candidate and a single principal stockholder for a significant portion of debt financing.
- Intellectual property litigation risks.
Investor Verification Checklist
- FDA Action Date: Verify the status of the FDA's review of the AFREZZA NDA and the December 29, 2010 target action date.
- Cash Runway: Confirm the company's ability to fund operations through Q1 2011 and the likelihood of securing additional financing before that date.
- Debt Covenants: Review the terms of the $350 million related-party loan, specifically the prepayment rights of the principal stockholder and interest rate adjustments upon default.
- Convertible Notes: Assess the impact of the $115 million senior convertible notes (due 2013) on potential dilution if converted.
- Supply Chain: Verify the status of the insulin supply agreement with Organon N.V. and the manufacturing capabilities at the Danbury facility.